2160 On Other Exchanges
2160 is not on other exchanges.

gni group ltd (2160) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GNI GROUP LTD (2160)

Related News

No related news articles were found.

gni group ltd (2160) Related Businessweek News

No Related Businessweek News Found

gni group ltd (2160) Details

GNI Group Ltd., a bio-pharma company, engages in the research, development, manufacturing, and sale of pharmaceutical drugs and traditional Chinese medicines in Asia. It offers Etuary, for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; diabetic nephropathy; and connective tissue disease associated interstitial lung disease. In addition, it is developing Tamibarotene for treating acute promyelocytic leukemia; F351 in Phase II clinical trials for the treatment of liver fibrosis, and in preclinical stage for the treatment of chronic kidney failure; and F573 for acute liver failure and acute-on-chronic liver failure. The company was founded in 2001 and is headquartered in Tokyo, Japan.

183 Employees
Last Reported Date: 03/29/17
Founded in 2001

gni group ltd (2160) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

gni group ltd
GNI Group Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for the Full Year Ending December 31, 2017

GNI Group Ltd. reported consolidated earnings results for the year ended December 31, 2016. For the period, the company reported revenue of JPY 1,306,931,000 compared to JPY 1,016,670,000 a year ago. Operating loss was JPY 276,361,000 compared to JPY 633,165,000 a year ago. Loss before tax was JPY 385,380,000 compared to JPY 669,623,000 a year ago. Loss for the year was JPY 465,694,000 compared to JPY 668,557,000 a year ago. Loss attributable to owners of the parent was JPY 513,101,000 compared to JPY 623,150,000 a year ago. Net loss per diluted share was JPY 4.44 compared to JPY 5.36 a year ago. Net cash flow used in operating activities was JPY 518,714,000 compared to JPY 382,203,000 a year ago. Purchases of property, plant and equipment was JPY 8,630,000 compared to JPY 279,559,000 a year ago. The primary factor for the reduction in the net loss was decreased operating loss due to higher gross profit. The company provided consolidated earnings guidance for the full year ending December 31, 2017. For the year, the company expects net sales of JPY 2,166 million, operating loss of JPY 53 million, loss before tax of JPY 19 million, loss for the year of JPY 138 million and loss attributable to owners of parent of JPY 263 million or JPY 1.21 per basic share.

GNI Group Ltd., Annual General Meeting, Mar 23, 2017

GNI Group Ltd., Annual General Meeting, Mar 23, 2017.

GNI Group Ltd. to Report Fiscal Year 2016 Results on Feb 15, 2017

GNI Group Ltd. announced that they will report fiscal year 2016 results on Feb 15, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2160 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2160.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2160 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GNI GROUP LTD, please visit www.gnipharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.